Changes in Functional Status
In contrast to the changes in left ventricular function, the changes in functional capacity produced by p-blockade in heart failure patients have been somewhat inconsistent. Although every study of >1 month's duration has shown improvement in functional classification,2 it has been difficult to demonstrate improved exercise capacity. Since p-antagonists block maximal heart rate increases, maximal workload will not be achieved in the presence of these agents. This appears to be especially cogent in the face of nonselective p-blockade. Since pB1-receptors are down-regulated in response to norepinephrine exposure, the P2-receptor may play a more prominent role in the failing heart.31 '32 37 Thus, the question whether differences in sudden death exist between selective and nonselective fl-blockers in patients with left ventricular dysfunction or injury is still unresolved. If such differences in sudden death do exist, one might postulate that incomplete deactivation of the sympathetic nervous system (an unblocked f,2-receptor), while beneficial to achieve a more appropriate exercise response in patients with heart failure, may be less beneficial with regard to survival. However, such differences have yet to be conclusively demonstrated.
Whether other properties of fl-blockers may impact favorably on survival is not known. It has been proposed that lipophilicity with penetration to the central nervous system may be of importance, since only fl-blockers with a higher degree of lipophilicity have shown significant effects on post-myocardial infarction survival. 42 In addition, the importance of vasodilator property has not been evaluated in these patients.
The CIBIS Trial
In this issue of Circulation, Lechat and associates present the primary outcome data from the Cardiac Insufficiency Bisoprolol Study ( 
CIBIS).18 This study is
See p 1765 the largest prospective heart failure mortality study of fl-blockade published to date. The authors of this study randomized 641 patients with heart failure of various causes to bisoprolol, a highly selective fl1-antagonist, or placebo. Patients had an ejection fraction <0.40 and were in New York Heart Association functional class III (95%) or IV (5%) at randomization. Participants received background therapy with diuretics and vasodilators (primarily angiotensin-converting enzyme inhibitors) and were followed for 1.9 years. The authors demonstrated the safety and tolerability of fl-blockade, even in very functionally impaired patients. The authors found no difference in overall mortality for fl-blockade versus placebo (relative risk, 0.80 [95% confidence interval, 0.56 to 1.15], P=.22). In addition, as with the MDC trial,15 no differences in sudden death were seen. However, subgroup analysis demonstrated a survival benefit of bisoprolol in those patients without a history of myocardial infarction or with a diagnosis of primary dilated cardiomyopathy. This finding is consistent with the more favorable hemodynamic effects of fl-blockade seen in patients with dilated versus ischemic cardiomyopathy.1016 Functional status of the patients on bisoprolol was improved, with less heart failure decompensation and hospitalization, a finding similar to that seen in the Metoprolol and Dilated Cardiomyopathy Trial.15 Unfortunately, the CIBIS trial was underpowered, thus leaving unanswered the question of a survival benefit of fl-blocking agents in subjects with heart failure. The trial was underpowered because (1) that these studies will have enough power to finally determine whether the frog is in fact a prince.
